688520 神州细胞
已收盘 11-15 15:00:00
资讯
新帖
简况
神州细胞-U11月15日遭主力抛售1463万元 环比增加137.89%
市场透视 · 11-15 15:20
神州细胞-U11月15日遭主力抛售1463万元 环比增加137.89%
神州细胞:安佳已与印尼、巴西等地伙伴签约,预计2025年开始在海外上市销售
财经网 · 11-14 15:28
神州细胞:安佳已与印尼、巴西等地伙伴签约,预计2025年开始在海外上市销售
神州细胞(688520)10月29日主力资金净卖出2933.88万元
证券之星 · 10-30
神州细胞(688520)10月29日主力资金净卖出2933.88万元
神州细胞(688520)2024年三季报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 10-30
神州细胞(688520)2024年三季报简析:营收净利润同比双双增长,盈利能力上升
国金证券:给予神州细胞买入评级
证券之星 · 10-29
国金证券:给予神州细胞买入评级
神州细胞八因子再创营利双增,RSV等多项研发蓄势中
国金证券 · 10-29
神州细胞八因子再创营利双增,RSV等多项研发蓄势中
神州细胞-U大跌5.15% 获主力净流出1236万元
智选洞察 · 10-29
神州细胞-U大跌5.15% 获主力净流出1236万元
神州细胞前三季度扭亏为盈
新京报 · 10-28
神州细胞前三季度扭亏为盈
神州细胞否认因涉嫌骗保被查,但其销售模式仍存争议
界面 · 10-28
神州细胞否认因涉嫌骗保被查,但其销售模式仍存争议
神州细胞(688520.SH)发布前三季度业绩,净利润1.5亿元
智通财经 · 10-28
神州细胞(688520.SH)发布前三季度业绩,净利润1.5亿元
神州细胞-U10月25日遭主力抛售2696万元 环比增加742.50%
市场透视 · 10-25
神州细胞-U10月25日遭主力抛售2696万元 环比增加742.50%
神州细胞-U10月23日主力资金流入883万元 连续5日加仓
市场透视 · 10-23
神州细胞-U10月23日主力资金流入883万元 连续5日加仓
神州细胞(688520.SH):重组呼吸道合胞病毒疫苗产品SCTV02注射液临床试验获批准
智通财经 · 10-22
神州细胞(688520.SH):重组呼吸道合胞病毒疫苗产品SCTV02注射液临床试验获批准
科技打头阵,如何低门槛布局科创板?
博时基金 · 10-22
科技打头阵,如何低门槛布局科创板?
神州细胞-U10月21日获主力加仓2285万元 环比增加5913.16%
市场透视 · 10-21
神州细胞-U10月21日获主力加仓2285万元 环比增加5913.16%
神州细胞-U涨5.33% 2024国际生物医药产业创新北京论坛将举行
智选洞察 · 10-21
神州细胞-U涨5.33% 2024国际生物医药产业创新北京论坛将举行
10月18日神州细胞-U涨5.07%,西部利得景程混合A基金重仓该股
证券之星 · 10-18
10月18日神州细胞-U涨5.07%,西部利得景程混合A基金重仓该股
神州细胞-U涨5.07%,华福证券一个月前给出“买入”评级,目标价62.84元
证券之星 · 10-18
神州细胞-U涨5.07%,华福证券一个月前给出“买入”评级,目标价62.84元
神州细胞: 关于公司业绩情况,请关注公司后续相关公告
证券之星 · 10-11
神州细胞: 关于公司业绩情况,请关注公司后续相关公告
10月11日神州细胞-U跌7.77%,西部利得景程混合A基金重仓该股
证券之星 · 10-11
10月11日神州细胞-U跌7.77%,西部利得景程混合A基金重仓该股
暂无数据
公司概况
公司名称:
北京神州细胞生物技术集团股份公司
所属行业:
医药制造业
上市日期:
2020-06-22
主营业务:
北京神州细胞生物技术集团股份公司是致力于研发具备差异化竞争优势生物药的创新型生物制药研发公司,专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品为重组蛋白药物、抗体药物等。公司在发现及研发创新药的领域拥有较强的能力,自主建立了从靶点蛋白筛选到候选药物的全套创新生物药发现上游技术平台体系。
发行价格:
25.64
{"stockData":{"symbol":"688520","market":"SH","secType":"STK","nameCN":"神州细胞","latestPrice":39.3,"timestamp":1731654000000,"preClose":41.26,"halted":0,"volume":3380051,"delay":0,"floatShares":445000000,"shares":445000000,"eps":-0.0587,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.96,"latestTime":"11-15 15:00:00","open":41.39,"high":41.88,"low":39.14,"amount":136000000,"amplitude":0.0664,"askPrice":39.31,"askSize":51,"bidPrice":39.3,"bidSize":113,"shortable":0,"etf":0,"ttmEps":-0.0587,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731893400000},"adr":0,"adjPreClose":41.26,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731634200000,1731641400000],[1731646800000,1731654000000]],"highLimit":45.39,"lowLimit":37.13,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":445335714,"pbRate":-40.85,"roa":"--","roe":"0.0%","epsLYR":-0.89,"committee":-0.423529,"marketValue":17502000000,"floatMarketCap":17502000000,"peRate":-669.505974,"changeRate":-0.0475,"turnoverRate":0.0076,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-11-18。","afterMarket":{"amount":0,"volume":0,"close":39.3,"buyVolume":0,"sellVolume":200,"time":1731656039464,"indexStatus":"已收盘 11-15 15:30:00","preClose":41.26}},"requestUrl":"/m/hq/s/688520/tweets","defaultTab":"tweets","newsList":[{"id":"2483317286","title":"神州细胞-U11月15日遭主力抛售1463万元 环比增加137.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483317286","media":"市场透视","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483317286?lang=zh_cn&edition=full","pubTime":"2024-11-15 15:20","pubTimestamp":1731655235,"startTime":"0","endTime":"0","summary":"11月15日, 神州细胞-U股价跌4.75%,报收39.30元,成交金额1.36亿元,换手率0.76%,振幅6.64%,量比0.61。神州细胞-U今日主力资金净流出1463万元,上一交易日主力净流出615万元,今日环比增加137.89%。该股近5个交易日下跌0.46%,主力资金累计净流出952万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出1010万元,其中净流出天数为10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115153519a23a269e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115153519a23a269e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2483469308","title":"神州细胞:安佳已与印尼、巴西等地伙伴签约,预计2025年开始在海外上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2483469308","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483469308?lang=zh_cn&edition=full","pubTime":"2024-11-14 15:28","pubTimestamp":1731569336,"startTime":"0","endTime":"0","summary":"11月14日,神州细胞举办2024年第三季度业绩说明会。对于海外布局,管理层表示,公司产品安佳因已与印尼、巴西等国家的区域合作伙伴签约,利用合作方在当地的临床、注册和销售经验,正在努力推进在当地的商业化进程,预计将于2025年开始陆续在海外上市销售,目前尚无法确定具体销售规模。中国患者整体治疗水平离国际标准还相差较大。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114153004a23685f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114153004a23685f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2479636293","title":"神州细胞(688520)10月29日主力资金净卖出2933.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479636293","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479636293?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:20","pubTimestamp":1730247621,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月29日收盘,神州细胞报收于38.01元,下跌6.82%,换手率1.28%,成交量5.72万手,成交额2.22亿元。近5日资金流向一览见下表:神州细胞融资融券信息显示,融资方面,当日融资买入1405.81万元,融资偿还967.03万元,融资净买入438.78万元。神州细胞主营业务:专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2479226914","title":"神州细胞(688520)2024年三季报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479226914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479226914?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:18","pubTimestamp":1730240284,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期神州细胞发布2024年三季报。截至本报告期末,公司营业总收入19.37亿元,同比上升40.44%,归母净利润1.5亿元,同比上升168.17%。按单季度数据看,第三季度营业总收入6.32亿元,同比上升10.7%,第三季度归母净利润2424.83万元,同比上升129.53%。本报告期神州细胞盈利能力上升,毛利率同比增幅0.81%,净利率同比增幅49.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000005928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2479414244","title":"国金证券:给予神州细胞买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479414244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479414244?lang=zh_cn&edition=full","pubTime":"2024-10-29 11:55","pubTimestamp":1730174114,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司赵海春,袁维近期对神州细胞进行研究并发布了研究报告《八因子再创营利双增,RSV等多项研发蓄势中》,本报告对神州细胞给出买入评级,当前股价为38.77元。 研发投入持续,管线丰富,创新RSV疫苗获批临床。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有4家机构给出评级,买入评级4家;过去90天内机构目标均价为62.84。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900018832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2479411519","title":"神州细胞八因子再创营利双增,RSV等多项研发蓄势中","url":"https://stock-news.laohu8.com/highlight/detail?id=2479411519","media":"国金证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479411519?lang=zh_cn&edition=full","pubTime":"2024-10-29 11:14","pubTimestamp":1730171685,"startTime":"0","endTime":"0","summary":"经营分析八因子再创营利双增,全年首次实现盈利在望。研发投入持续,管线丰富,创新RSV疫苗获批临床。公司目前4个产品获批,3个疫苗品种被国家纳入紧急使用,还有重组蛋白、双抗等诸多管线在研。除公司在自免领域有白介素等新产品在国内外展开临床外,2024年10月23日,公司又公告新增RSV疫苗获批临床。维持“买入”评级。风险提示新药研发及商业推广不达预期、对外合作不达预期等风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029113909a1f3de60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029113909a1f3de60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2479149753","title":"神州细胞-U大跌5.15% 获主力净流出1236万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479149753","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479149753?lang=zh_cn&edition=full","pubTime":"2024-10-29 09:50","pubTimestamp":1730166630,"startTime":"0","endTime":"0","summary":"10月29日,神州细胞-U股价大幅下跌,截至09点50分,神州细胞-U下跌5.15%,报38.69元/股,失守40元整数关口,成交6950万元,换手率0.39%。资金动向截止发稿,神州细胞-U获得主力净流出1236万元,其中超大单流出477万元,大单流出758万元。最新财报显示,今年三季报,神州细胞-U实现营业收入19.37亿元,同比增长40.44%,净利润为1.50亿元,同比增长168.17%,基本每股收益为0.34元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029095054ab7d0955&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029095054ab7d0955&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2478428488","title":"神州细胞前三季度扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2478428488","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478428488?lang=zh_cn&edition=full","pubTime":"2024-10-28 20:21","pubTimestamp":1730118073,"startTime":"0","endTime":"0","summary":"新京报讯 10月28日,神州细胞发布2024年第三季度报告。今年前三季度,公司实现营业收入19.37亿元,同比增加40.44%;归属于上市公司股东的净利润1.5亿元;基本每股收益0.34元。其中,第三季度实现营业收入6.32亿元,同比增长10.7%;归属于上市公司股东的净利润2424.83万元。神州细胞称,营收增长主要因公司产品销售收入稳定增长所致。净利润较上年同期扭亏为盈,主要系公司产品销售收入稳定增长,以及通过控制运营成本、提高研发效率等方式降本增效所致。文章来源:新京报原标题:神州细胞前三季度扭亏为盈","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028210027ab7bb27b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028210027ab7bb27b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2478993170","title":"神州细胞否认因涉嫌骗保被查,但其销售模式仍存争议","url":"https://stock-news.laohu8.com/highlight/detail?id=2478993170","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478993170?lang=zh_cn&edition=full","pubTime":"2024-10-28 18:16","pubTimestamp":1730110599,"startTime":"0","endTime":"0","summary":"据业内消息,因在核心产品安佳因销售过程中涉嫌骗保,神州细胞多位医药代表和地区经理已被警方带走调查。不到三年时间,神州细胞安佳因就创造了销售“神话”。据神州细胞2023年年报,2023年,神州细胞安佳因已占据同类产品市场占有率第一,实现销售额约17.8亿元。此外,神州细胞还曾通过另一项名为德义慈善“神州友爱-血友病患者援助”项目完成安佳因的销售现金返还。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028181811a1f1d2c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028181811a1f1d2c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2478178277","title":"神州细胞(688520.SH)发布前三季度业绩,净利润1.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478178277","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478178277?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:19","pubTimestamp":1730103589,"startTime":"0","endTime":"0","summary":"智通财经APP讯,神州细胞(688520.SH)发布2024年第三季度报告,公司前三季度营业收入19.37亿元,同比增长40.44%;归属于上市公司股东的净利润1.5亿元;归属于上市公司股东的扣除非经常性损益的净利润4.62亿元,同比增长4778%;基本每股收益0.34元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688520"],"gpt_icon":0},{"id":"2478267137","title":"神州细胞-U10月25日遭主力抛售2696万元 环比增加742.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478267137","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478267137?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:19","pubTimestamp":1729840766,"startTime":"0","endTime":"0","summary":"10月25日, 神州细胞-U股价跌1.13%,报收40.34元,成交金额1.70亿元,换手率0.95%,振幅3.80%,量比1.11。神州细胞-U今日主力资金净流出2696万元,上一交易日主力净流出320万元,今日环比增加742.50%。该股近5个交易日上涨5.88%,主力资金累计净流入1712万元;近20日主力资金累计净流出1.35亿元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025153649a1e9507e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025153649a1e9507e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2477706375","title":"神州细胞-U10月23日主力资金流入883万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2477706375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477706375?lang=zh_cn&edition=full","pubTime":"2024-10-23 15:18","pubTimestamp":1729667908,"startTime":"0","endTime":"0","summary":"10月23日, 神州细胞-U股价涨2.90%,报收41.16元,成交金额1.55亿元,换手率0.86%,振幅4.92%,量比1.12。神州细胞-U今日主力资金净流入883万元,连续5日净流入,上一交易日主力净流入1558万元,今日环比减少43.32%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为40.00%,平均涨幅为1.63%。该股近5个交易日上涨13.01%,主力资金累计净流入5428万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出1.03亿元,其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410231529429f5869f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410231529429f5869f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2477021328","title":"神州细胞(688520.SH):重组呼吸道合胞病毒疫苗产品SCTV02注射液临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2477021328","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477021328?lang=zh_cn&edition=full","pubTime":"2024-10-22 16:49","pubTimestamp":1729586943,"startTime":"0","endTime":"0","summary":"智通财经APP讯,神州细胞(688520.SH)发布公告,公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,同意公司自主研发的重组呼吸道合胞病毒疫苗产品SCTV02注射液在≥18周岁的健康人群中开展预防因呼吸道合胞病毒感染导致的呼吸道疾病的临床试验。呼吸道合胞病毒(RSV)可以引起全年龄段人群的呼吸道感染,常见症状包括咳嗽、咳痰、喘息和发热,是全球引起5岁以下儿童、老年人及免疫功能低下人群急性下呼吸道感染的重要病原体,目前尚无特异性抗病毒治疗药物。SCTV02注射液是公司以差异化竞争优势为目标自主开发的预防RSV感染所致呼吸道疾病的重组蛋白疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1583","03347","BK1576","159646","BK0239","688520"],"gpt_icon":0},{"id":"2477841980","title":"科技打头阵,如何低门槛布局科创板?","url":"https://stock-news.laohu8.com/highlight/detail?id=2477841980","media":"博时基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477841980?lang=zh_cn&edition=full","pubTime":"2024-10-22 07:55","pubTimestamp":1729554913,"startTime":"0","endTime":"0","summary":"多家A股半导体行业上市公司披露了2024年前三季度业绩预告,业绩普遍预喜。科创100指数ETF只需要开通上海证券交易所基金账户,且满足交易风险评级要求,即可参与交易。ETF基金的过往业绩及其净值高低并不预示其未来业绩表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688578","688536","688516","688146","688198","688232","000698","688439","688055","688408","688276","688772","688208","688139","688366","688387","688739","688083","688289","688019","688052","688336","688192","688425","688484","688141","688166","688433","688172","688549","688690","688281","688050","588030","688582","688006","688789","688029","688717","688278","688432","688100","688617","688779","688327","688110","688331","688568","688400","688798","688778","688032","688567","688639","688088","688007","688498","688326","688352","688200","688027","688107","688147","688333","688608","688548","688235","688017","688063","159982","688037","688347","688005","688066","688097","688700","688409","688318","688348","688361","688686","688248","688153","688105","688062","688526","688106","688177","688016","688266","688343","688001","688048","688612","688213","688556","688443","688520","688322","688161","688702","688575","688390","688002"],"gpt_icon":0},{"id":"2477884374","title":"神州细胞-U10月21日获主力加仓2285万元 环比增加5913.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477884374","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477884374?lang=zh_cn&edition=full","pubTime":"2024-10-21 15:18","pubTimestamp":1729495129,"startTime":"0","endTime":"0","summary":"10月21日, 神州细胞-U股价涨3.31%,报收39.36元,成交金额1.83亿元,换手率1.05%,振幅6.25%,量比1.49。神州细胞-U今日主力资金净流入2285万元,连续3日净流入,上一交易日主力净流入38万元,今日环比增加5913.16%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为61.54%,平均涨幅为2.25%。该股近5个交易日上涨2.69%,主力资金累计净流入2582万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流出1.20亿元,其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102115321495b800c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102115321495b800c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2477008403","title":"神州细胞-U涨5.33% 2024国际生物医药产业创新北京论坛将举行","url":"https://stock-news.laohu8.com/highlight/detail?id=2477008403","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477008403?lang=zh_cn&edition=full","pubTime":"2024-10-21 13:00","pubTimestamp":1729486835,"startTime":"0","endTime":"0","summary":"10月21日,神州细胞-U股价大幅上涨,截至13点00分,神州细胞-U上涨5.33%,报40.13元/股,突破40元整数关口,成交1.17亿元,换手率0.68%,振幅5.93%。消息解读10月23日-26日,2024国际生物医药产业创新北京论坛将在北京经济技术开发区举行。主营业务及业绩神州细胞-U公司主营业务为恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241021130257a1e22630&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241021130257a1e22630&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161726","399441","BK0239","688520"],"gpt_icon":0},{"id":"2476472265","title":"10月18日神州细胞-U涨5.07%,西部利得景程混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2476472265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476472265?lang=zh_cn&edition=full","pubTime":"2024-10-18 16:23","pubTimestamp":1729239808,"startTime":"0","endTime":"0","summary":"证券之星消息,10月18日神州细胞-U涨5.07%,收盘报38.1元,换手率1.02%,成交量4.53万手,成交额1.7亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为西部利得景程混合A。西部利得景程混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101800026017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2476447229","title":"神州细胞-U涨5.07%,华福证券一个月前给出“买入”评级,目标价62.84元","url":"https://stock-news.laohu8.com/highlight/detail?id=2476447229","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476447229?lang=zh_cn&edition=full","pubTime":"2024-10-18 16:23","pubTimestamp":1729239802,"startTime":"0","endTime":"0","summary":"今日神州细胞-U涨5.07%,收盘报38.1元。2024年8月25日,华福证券研究员盛丽华发布了对神州细胞的研报《重组VIII因子放量,业绩有望持续释放》,该研报对神州细胞给出“买入”评级,认为其目标价为62.84元,现价距离目标价尚有64.93%的涨幅空间。给予公司2024年10倍PS,合理市值为280亿,对应目标价格为62.84元,维持“买入”评级。神州细胞-U个股概况:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101800026011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688520"],"gpt_icon":0},{"id":"2474064028","title":"神州细胞:\n关于公司业绩情况,请关注公司后续相关公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2474064028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474064028?lang=zh_cn&edition=full","pubTime":"2024-10-11 19:00","pubTimestamp":1728644459,"startTime":"0","endTime":"0","summary":"证券之星消息,神州细胞10月11日在投资者关系平台上答复投资者关心的问题。关于公司业绩情况,请关注公司后续相关公告。14价HPV疫苗受试者已完成第三针接种,现正处在随访阶段,相关研发进展及数据分析等属于公司自愿披露信息,公司将依法依规,视业务进展情况开展相关信息披露工作。公司目前生产经营情况正常,计划于10月29日披露第三季度报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101100031926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2474205401","title":"10月11日神州细胞-U跌7.77%,西部利得景程混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474205401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474205401?lang=zh_cn&edition=full","pubTime":"2024-10-11 16:22","pubTimestamp":1728634924,"startTime":"0","endTime":"0","summary":"证券之星消息,10月11日神州细胞-U跌7.77%,收盘报38.0元,换手率0.92%,成交量4.1万手,成交额1.59亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为西部利得景程混合A。西部利得景程混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101100023638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-06-22","address":"北京市通州区北京经济技术开发区科创七街31号院5号楼307","stockEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":0.0791},{"period":"3month","weight":0.0965},{"period":"6month","weight":-0.1637},{"period":"1year","weight":-0.2291},{"period":"ytd","weight":-0.2705}],"companyName":"北京神州细胞生物技术集团股份公司","boardCode":"AI0027","perCapita":"43253股","boardName":"医药制造业","registeredCapital":"44533万元","compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.0399},{"period":"3month","weight":0.1567},{"period":"6month","weight":0.056},{"period":"1year","weight":0.0917},{"period":"ytd","weight":0.1196}],"survey":" 北京神州细胞生物技术集团股份公司是致力于研发具备差异化竞争优势生物药的创新型生物制药研发公司,专注于恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品为重组蛋白药物、抗体药物等。公司在发现及研发创新药的领域拥有较强的能力,自主建立了从靶点蛋白筛选到候选药物的全套创新生物药发现上游技术平台体系。","serverTime":1731791775028,"listedPrice":25.64,"stockholders":"10296人(较上一季度增加3.33%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神州细胞,688520,神州细胞股票,神州细胞股票老虎,神州细胞股票老虎国际,神州细胞行情,神州细胞股票行情,神州细胞股价,神州细胞股市,神州细胞股票价格,神州细胞股票交易,神州细胞股票购买,神州细胞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}